

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/753,869	01/03/2001	Richard Griffey	IBIS-0339	1982		
34138 759	90 12/30/2003	•	EXAM	EXAMINER		
COZEN O'CONNOR, P.C. 1900 MARKET STREET			BORIN, MICHAEL L			
	A, PA 19103-3508		ART UNIT PAPER NUMBER			
	·		1631			
		•	DATE MAILED: 12/30/2001	DATE MAILED: 12/30/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .		Applicant(s)				
	09/753,869		GRIFFEY ET AL.				
Office Action Summary	Examiner		Art Unit				
	Michael Borin		1631				
The MAILING DATE of this communication appears on the cover sheet with the correspond nce address							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)⊠ Responsive to communication(s) filed on <u>21 October 2003</u> .							
2a) This action is FINAL . 2b) This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>12</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) <u>12</u> is/are rejected.							
7) ☐ Claim(s) is/are objected to.							
<u> </u>							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. §§ 119 and 120							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application)							
since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.							
37 CFR 1.78.							
a) The translation of the foreign language provisional application has been received.							
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) 🔲 🛭	Interview Summary	(PTO-413) Paper No(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) 🔲 🛚	Notice of Informal P	atent Application (PTC				
3) LI Information Disclosure Statement(s) (PTO-1449) Paper No(s) _	6) ∐ (Other: .					

U.S. Patent and Trademark Office PTOL-326 (Rev. 11-03)

Page 2 Serial Number: 09/753869

Art Unit: 1631

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/21/2003 has been entered.

Status of Claims

2. Claim 12 is pending.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C.102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States-

3. Claim 12 is rejected under 35 U.S.C. 103(a) as obvious over Walters et al

The instant claim is drawn to method of identifying in silico compounds of a virtual library comprising steps of:

Serial Number: 09/753869 Page 3

Art Unit: 1631

a) dissecting a compound into fragments,

b) adding fragments in sequential synthesis rounds,

c) tracking the addition of the fragments.

Walters et al reviews different strategies of virtual screening. One of the strategies, "chemically aware builder" comprises presenting components of the virtual library as combination of reagents and corresponding reactions. As such the method reads on the claimed method wherein a compound is defined by synthetic rounds between its chemical components. Further, the review describes another software, "Computer-Aided Estimation of Synthetic Accessibility", that evaluates members of the library by their synthesizability, i.e., by their building blocks and chemical reactions among them.

Although neither of the methods discussed above requires characterization of each compound of the library (as the instant method does), it would be *prima facie* obvious to one skilled in art to characterized any compound of interest, and thus to extend, if needed, such characterization to each compound of the library.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent

Serial Number: 09/753869 Page 4

Art Unit: 1631

the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321[©] may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claim 12 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 8,9 of U. S. Patent No. 6253168. Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claim is drawn to method of identifying *in silico* compounds of a virtual library comprising steps of:

- a) dissecting a compound into fragments,
- b) adding fragments in sequential synthesis rounds,
- c) tracking the addition of the fragments.
- U. S. Patent No. 6253168 teaches method of generating database comprising information about member compound of a virtual library comprising steps of
- a) selecting each of said compounds for said virtual library and, for each,

Serial Number: 09/753869 Page 5

Art Unit: 1631

dissecting each of said compounds into fragments;

b) linking together the fragments of each of the compounds;

c) tracking the sequence of linkage for each compound.

Even though the claims of '168 patent do not address identifying *in silico* compounds, generating the database information as claimed in '168 will, therefore, obviously describe (identify) the member compound; further, the method steps of the instant and referenced claims are the same.

Conclusion.

5. No claims are allowed

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (703) 305-4506. Dr. Borin can normally be reached between the hours of 8:30 A.M. to 5:00 P.M. EST Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on

(703) 308-4028. The fax telephone number for this group is (703) 305-3014.

Art Unit: 1631

Any inquiry of a general nature or relating the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

December 22, 2003

MICHAEL BORIN, PH.D PRIMARY EXAMINER

mlb